Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Non-Current Deffered Revenue (2018 - 2026)

10x Genomics' Non-Current Deffered Revenue history spans 6 years, with the latest figure at $10.5 million for Q4 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 16.08% to $10.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.5 million, a 16.08% decrease, with the full-year FY2025 number at $10.5 million, down 16.08% from a year prior.
  • Non-Current Deffered Revenue hit $10.5 million in Q4 2025 for 10x Genomics, down from $10.9 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for TXG hit a ceiling of $12.6 million in Q1 2025 and a floor of $3.2 million in Q4 2022.
  • Historically, Non-Current Deffered Revenue has averaged $10.3 million across 4 years, with a median of $11.1 million in 2025.
  • Biggest five-year swings in Non-Current Deffered Revenue: surged 178.48% in 2023 and later decreased 16.08% in 2025.
  • Tracing TXG's Non-Current Deffered Revenue over 4 years: stood at $3.2 million in 2022, then surged by 178.48% to $8.8 million in 2023, then soared by 41.97% to $12.5 million in 2024, then decreased by 16.08% to $10.5 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for TXG at $10.5 million in Q4 2025, $10.9 million in Q3 2025, and $11.3 million in Q2 2025.